W
WAVEMAN · COMPANY
BWAY · Brainsway Ltd.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

BWAY

Brainsway Ltd.
MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001505065
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
24
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
3
codes C/M, not in net · no price filed
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
24 funds added or opened last quarter
below 71% of Medical Devices
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
0.3% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
below 84% of Medical Devices
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +90.4%
+90.4%12M
-5%+39%+82%+125%2025-092025-102025-122026-032026-052026-072026-09 2026-06-15 · Moiseyev Gilad sold -2026-06-02 · Roth Yiftach sold -2026-06-02 · Roth Yiftach sold -2026-06-01 · Roth Yiftach sold -2026-05-26 · Mitrany Rayten Michal Ety sold -2026-05-25 · Mitrany Rayten Michal Ety sold -
INSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 24 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
TMOPENROKBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDX
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Brainsway Ltd. in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Moiseyev Gilad
Chief Technology Officer
SELL
2026-06-15
5,000.0
-
Roth Yiftach
Chief Scientist
SELL
2026-06-02
2,000.0
-
Roth Yiftach
Chief Scientist
SELL
2026-06-02
1,000.0
-
Roth Yiftach
Chief Scientist
SELL
2026-06-01
2,000.0
-
Mitrany Rayten Michal Ety
Director
SELL
2026-05-26
7,980.0
-
6 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 1 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Valor Management LLC
5,314,950.0 sh
$82.4M
MASTERS CAPITAL MANAGEMENT LLC
1,500,000.0 sh
$23.3M
ESSEX INVESTMENT MANAGEMENT CO LLC
592,606.0 sh
$9.2M
RENAISSANCE TECHNOLOGIES LLC
475,920.0 sh
$7.4M
Cresset Asset Management, LLC
314,924.0 sh
$4.9M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
1290 Essex Small Cap Growth Fund
$2.3M POSITION · AS OF 2026-04-30
2.0%
ARK Israel Innovative Technology ETF
$2.4M POSITION · AS OF 2026-04-30
1.7%
Timothy Plan Israel Common Values Fund
$2.3M POSITION · AS OF 2026-03-31
1.2%
Royce Smaller-Companies Growth Fund
$1.3M POSITION · AS OF 2026-03-31
0.7%
Even Herd Long Short ETF
$200.1K POSITION · AS OF 2026-03-31
0.3%
Steward Values Enhanced International Fund
$419.8K POSITION · AS OF 2026-04-30
0.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 2 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release
2
Not applicable
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2024-122023-122022-122021-12
GROSS PROFIT$30.6M$23.5M$20.0M$23.1M
NET INCOME$2.9M$-4.2M$-13.3M$-6.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →